Pharmacyclics Insider Heow Tan Unloads 10,000 Shares (PCYC)
Pharmacyclics (NASDAQ:PCYC) Insider Heow Tan sold 10,000 shares of Pharmacyclics stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $123.58, for a total value of $1,235,800.00. Following the sale, the insider now directly owns 1,873 shares in the company, valued at approximately $231,465. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Pharmacyclics (NASDAQ:PCYC) traded up 3.97% on Wednesday, hitting $123.43. The stock had a trading volume of 689,961 shares. Pharmacyclics has a 1-year low of $82.51 and a 1-year high of $154.89. The stock’s 50-day moving average is $103.0 and its 200-day moving average is $108.1. The company has a market cap of $9.290 billion and a price-to-earnings ratio of 106.09.
Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Thursday, July 31st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 106.6% on a year-over-year basis. Analysts expect that Pharmacyclics will post $0.36 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Pharmacyclics currently has an average rating of “Buy” and an average target price of $155.33.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Receive News & Ratings for Pharmacyclics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.